Trial · NCT04492514
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
NCT04492514, Phase 2, Completed, Kristin Hudock; results first posted 2024-12-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation. Trials, record NCT04492514. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04492514
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
- NCT number
- NCT04492514
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Kristin Hudock
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Interventions
- Mavrilimumab, Placebo
- First posted
- 2020-07-30
- Last updated
- 2024-12-09
- Results first posted
- 2024-12-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Subjects Alive and Off Oxygen at 14 Days | 14 days | Number of subjects alive and off of oxygen |
| Secondary | Proportion of Subjects Alive and Without Respiratory Failure at 28 Days | 28 days | Number of subjects alive and without respiratory failure |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Subjects Alive and Off Oxygen at 14 Days | 14 days | Only 1 participant was enrolled at our site and this individual received Mavrilimumab. We did not enroll any patients into the placebo group. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Proportion of Subjects Alive and Without Respiratory Failure at 28 Days | 28 days | Only 1 participant was enrolled at our site and this individual received Mavrilimumab. We did not enroll any patients into the placebo group. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Subjects Alive and Off Oxygen at 14 Days | Mavrilimumab | 1 | Participants | ||
| Proportion of Subjects Alive and Off Oxygen at 14 Days | Placebo | 0 | Participants | ||
| Proportion of Subjects Alive and Without Respiratory Failure at 28 Days | Mavrilimumab | 1 | Participants | ||
| Proportion of Subjects Alive and Without Respiratory Failure at 28 Days | Placebo | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mavrilimumab | 1 | |
| Overall Study | STARTED | Placebo | 0 | |
| Overall Study | COMPLETED | Mavrilimumab | 1 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Mavrilimumab | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Chest Cold | Respiratory, thoracic and mediastinal disorders | Mavrilimumab | 1 | 1 | 1 |
| other | Chest Cold | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 0 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mavrilimumab | 0 | 1 |
| Total, all-cause mortality | Placebo | 0 | 0 |
| Total, other adverse events | Mavrilimumab | 1 | 1 |
| Total, other adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Mavrilimumab | 0 | 1 |
| Total, serious adverse events | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33754144 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04492514
GET https://conductscience.org/api/trials/v1/NCT04492514/registered